What Is CJC-1295? Mechanism, Uses, Risks, and FDA Status
What Is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH) consisting of 29 amino acids. Originally developed by ConjuChem Biotechnologies, it was designed to have a significantly longer half-life than natural GHRH through a modification called Drug Affinity Complex (DAC) technology, which allows it to bind to serum albumin. This extends its biological activity from minutes to approximately 6–8 days, enabling sustained elevation of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. CJC-1295 is one of the most widely studied GHRH analogs in the peptide research space.
How Does CJC-1295 Work?
CJC-1295 functions by binding to GHRH receptors on the anterior pituitary gland, stimulating the release of growth hormone in a pulsatile fashion that mimics the body's natural secretion pattern. The DAC modification creates a covalent bond with albumin in the bloodstream, dramatically extending the peptide's half-life compared to native GHRH (which is degraded within minutes).
Research suggests this mechanism produces several downstream effects:
- Sustained GH elevation — Unlike single-bolus GH injections, CJC-1295 promotes multiple GH pulses over days
- IGF-1 upregulation — Elevated GH stimulates hepatic production of IGF-1, a key mediator of growth and repair
- Preserved pulsatility — The hypothalamic-pituitary feedback loop remains intact, reducing the risk of GH receptor desensitization
A key clinical study by Teichman et al. (J Clin Endocrinol Metab, 2006) demonstrated that a single injection of CJC-1295 increased mean GH levels 2- to 10-fold for 6 days and increased IGF-1 levels 1.5- to 3-fold for 9–11 days in healthy adults.
What Is CJC-1295 Used For?
Based on published research, CJC-1295 has been investigated for:
- Growth hormone deficiency — As a potential alternative to daily GH injections, offering less frequent dosing
- Body composition — Preliminary data shows increased lean body mass and reduced adiposity in clinical subjects (Ionescu & Bhatt, Growth Horm IGF Res, 2006)
- Age-related GH decline — Research into restoring youthful GH pulsatility in older adults
- Recovery and repair — Elevated IGF-1 may support tissue repair, though direct evidence in this context is limited
- Sleep quality — GH is primarily released during slow-wave sleep; some research suggests GHRH analogs may enhance sleep architecture
A variant without the DAC modification (often called "CJC-1295 no DAC" or Mod GRF 1-29) has a shorter half-life of approximately 30 minutes and is frequently combined with GH secretagogues like Ipamorelin for synergistic effects.
What Are the Risks and Side Effects?
- Injection site reactions — Redness, swelling, and induration at the injection site were the most common adverse events in clinical trials
- Water retention — Elevated GH can cause fluid retention, joint stiffness, and peripheral edema
- Flushing and warmth — Transient facial flushing reported in some subjects
- Numbness and tingling — Paresthesias have been noted, likely related to fluid shifts
- Potential for GH-related concerns — Prolonged supraphysiological GH/IGF-1 elevation raises theoretical concerns about insulin resistance and cellular proliferation, though clinical trials of CJC-1295 did not demonstrate these effects at studied doses
- Limited long-term safety data — The longest published trial was 60–90 days; long-term effects remain unknown
- One serious adverse event — A Phase II clinical trial was halted after a participant death, though the relationship to CJC-1295 was not definitively established
FDA Status
CJC-1295 is classified as investigational. It has not received FDA approval for any indication. It was studied in Phase I/II clinical trials but development was discontinued. CJC-1295 is currently available through compounding pharmacies under physician prescription as a bulk compounding ingredient, though its regulatory status may evolve. For the latest regulatory updates, visit our FDA tracker.
Key Studies and Evidence Base
| Study | Finding | |-------|---------| | Teichman et al., 2006 (JCEM) | Single dose increased GH 2–10x for 6 days in healthy adults | | Ionescu & Bhatt, 2006 | Dose-dependent increases in IGF-1 sustained over 9–11 days | | Alba et al., 2006 (JCEM) | Weekly dosing maintained elevated IGF-1 without tachyphylaxis over 60 days |
The Bottom Line
CJC-1295 is a well-characterized GHRH analog with robust clinical evidence demonstrating sustained GH and IGF-1 elevation from infrequent dosing. While early-phase human trials showed promising results for body composition and GH restoration, development was discontinued and long-term safety data is lacking. It remains available through compounding pathways but should only be used under medical supervision with appropriate monitoring of GH, IGF-1, glucose, and other relevant biomarkers.
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. TruPeptide does not sell peptides or facilitate purchases.